



U.S. Food and Drug Administration  
Office of Regulatory Affairs  
12420 Parklawn Dr.  
Rockville, MD 20852  
[www.fda.gov](http://www.fda.gov)

Via UPS Worldwide Saver (Express)  
Return Receipt Requested

29 May 2020

Mr. Roberto Andreoni  
President  
Redox S.R.L.  
Viale Stucchi, 62/26  
20090 Monza (MB) Italy

Dear Mr. Andreoni:

The U.S. Food and Drug Administration (FDA) reviewed an inspection conducted by Agenzia Italiana del Farmaco (AIFA) at Redox S.R.L., located at Viale Stucchi, 62/26 - 20090 Monza (MB), from 22 – 24 May 2019. FDA has determined that the inspection classification of this facility is "voluntary action indicated" ("VAI").<sup>1</sup> Based on this inspection, this facility is considered to be in a minimally acceptable state of compliance with regards to current good manufacturing practice (CGMP).

A VAI inspection classification indicates that, although documented objectionable conditions were found during the inspection, FDA will not take or recommend regulatory or enforcement action because the objectionable conditions do not meet the threshold for action at this time. Despite this facility inspection classification, FDA recommends that you address any deviations noted during the inspection or otherwise conveyed to you following the inspection. If not corrected, the same or similar conditions could lead to a future inspection being classified as "official action indicated" ("OAI").

This letter is not intended as an endorsement or certification of the facility. It remains your responsibility to ensure continued compliance with CGMP.

An inspection classification of VAI for CGMP compliance will not directly negatively impact FDA's assessment of any pending marketing application referencing this facility. Please note, however, that application approval will depend on a product- and application-specific facility assessment conducted by the appropriate CDER or CVM review office. This letter does not address or reflect FDA's decision making with respect to any potential non-CGMP compliance issues.

FDA has concluded that this inspection is "closed" under 21 CFR 20.64(d)(3). If you have any questions regarding this letter, please contact: [ORAMRAInspectionReview@fda.hhs.gov](mailto:ORAMRAInspectionReview@fda.hhs.gov).

Sincerely,

Ann M.

Montemurro

Ann Marie Montemurro

Director, Division of Pharmaceutical Quality Programs

Digitally signed by Ann M. Montemurro-S  
DN: c=US, o=U.S. Government, ou=HHS,  
ou=FDA, ou=People,  
8.9.2342.19200300.100.1.1=2000095112,  
cn=Ann M. Montemurro-S  
Date: 2020.05.29 15:03:36 -04'00'

FEL: 3006720740

<sup>1</sup> See Inspection Classification Definitions at <http://www.fda.gov/ICECI/Inspections/ucm223231.htm>